Author
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
8 papers
Recent·Most cited
Z. Yang, B. A. Johnson, V. A. Meliopoulos, X. Ju, P. Zhang, M. P. Hughes, J. Wu, K. P. Koreski, T.-C. Chang, G. Wu, J. Hixon, J. Duffner, K. Wong, R. Lemieux, K. G. Lokugamage, , J. P. Taylor
This study identifies the role of G3BP1-N interaction in SARS-CoV-2 replication by showing that disrupting this interaction reduces viral replication and pathogenesis.
bioRxiv · Jun 29, 2023 · PreprintCell Biology
M. N. Vu, R. E. Alvarado, D. R. Morris, K. G. Lokugamage, Y. Zhou, A. L. Morgan, L. K. Estes, A. M. McLeland, C. Schindewolf, J. A. Plante, Y. P. Ahearn, W. M. Meyers, J. T. Murray, S. Weaver, D. H. Walker, , V. D. Menachery
This study identifies the N679K mutation in Omicron variants as reducing spike protein expression and attenuating SARS-CoV-2 infection, while showing a replication advantage in the upper airway.
bioRxiv · Apr 17, 2023Microbiology
B. A. Johnson, Y. Zhou, K. G. Lokugamage, M. N. Vu, N. E. Bopp, P. A. Crocquet-Valdes, B. Kalveram, C. Schindewolf, Y. Liu, D. Scharton, J. A. Plante, X. Xie, P. Aguilar, S. Weaver, P.-Y. Shi, , V. D. Menachery
This study shows that mutations in the SARS-CoV-2 nucleocapsid protein enhance viral replication and pathogenesis by increasing phosphorylation and resisting kinase inhibition.
PLOS Pathogens · Jun 21, 2022Peer-reviewedMicrobiology
K. G. Lokugamage, A. Hage, M. Devries, A. M. Vallero-Jimenez, C. Schindewolf, M. Dittmann, R. Rajsbaum, V. D. Menachery
This study compares the sensitivity of SARS-CoV-2 and SARS-CoV to type I interferon, finding SARS-CoV-2 is more susceptible to IFN-I treatment.
Journal of Virology · Nov 9, 2020Peer-reviewedMicrobiology
P.-Y. Shi, X. Xie, A. E. Muruato, X. Zhang, K. G. Lokugamage, C. R. Fontes-Garfias, J. Zou, J. Liu, P. Ren, M. Balakrishnan, T. Cihlar, C.-T. K. Tseng, S. Makino, V. D. Menachery, J. P. Bilello
This paper develops a high-throughput assay using a nanoluciferase-modified SARS-CoV-2 virus to rapidly test neutralizing antibodies and antiviral drugs.
Nature Communications · Oct 15, 2020Peer-reviewedMicrobiology
J. A. Plante, Y. Liu, J. Liu, H. Xia, B. A. Johnson, K. G. Lokugamage, X. Zhang, A. E. Muruato, J. Zou, C. R. Fontes-Garfias, D. Mirchandani, D. Scharton, J. P. Bilello, Z. Ku, Z. An, , P.-Y. Shi
This study shows the D614G mutation in SARS-CoV-2 increases viral replication and upper respiratory tract viral loads but does not reduce vaccine efficacy or antibody neutralization.
bioRxiv · Sep 1, 2020Microbiology
B. A. Johnson, X. Xie, B. Kalveram, K. G. Lokugamage, A. Muruato, J. Zou, X. Zhang, T. Juelich, J. K. Smith, L. Zhang, C. Schindewolf, M. N. Vu, A. Vanderheiden, J. A. Plante, K. S. Plante, , V. D. Menachery
This study shows that removing the furin cleavage site from SARS-CoV-2 increases replication in Vero cells but reduces replication in respiratory cells and pathogenesis in hamsters, while also decreasing neutralization susceptibility.
bioRxiv · Aug 26, 2020 · PreprintMicrobiology
J. Harcourt, A. Tamin, X. Lu, S. Kamili, S. Kumar Sakthivel, L. Wang, J. Murray, K. Queen, B. Lynch, B. Whitaker, Y. Tao, C. Paden, J. Zhang, Y. Li, A. Uehara, , N. J. Thornburg
The paper isolates and characterizes SARS-CoV-2 from the first US COVID-19 patient, showing high replication in Vero cells and depositing the strain for public use.
bioRxiv · Mar 2, 2020 · PreprintMicrobiology